Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant vs Neoadjuvant Pembrolizumab in Stage III-IV Melanoma
NCT03698019Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2019
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by National Cancer Institute. Started Feb 2019; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03698019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698019.